Skip to main content
Grant Details

Grant Number: 5R03CA085435-02 Interpret this number
Primary Investigator: Imperato-Mc Ginley, Julianne
Organization: Weill Medical College Of Cornell Univ
Project Title: Androgens Regulate Igf Pathway and Prostate Diseases
Fiscal Year: 2001
Back to top


Abstract

DESCRIPTION (Applicant's Description) Both androgens and growth factors are important in prostate differentiation and growth. Insulin-like growth factors, IGF-I and TGF-II, acting through the IGF-I receptor are mitogenic and antiapoptotic to prostate epithelial cells. Androgens and IGFs interact to mutually potentiate their effects. Blocking conversion of testosterone to 5 alpha-dihydrotestosterone (DHT), inhibits prostatic IGF-I and IGF-I receptor gene expression while inducing IGFBP-3 gene expression. Conversely, IGF-I induces 5 alpha-reductase isozyme expression which converts testosterone to DHT in tissue culture and directly activates the androgen receptor. Animal and human studies suggest that androgens may increase circulating levels of IGF-I as well as prostatic IGF-I, IGF-II and IGF-I receptor gene expression. Also, circulating IGF-I levels are higher in benign prostate hyperplasia (BPH) and prostate cancer, both androgen mediated conditions. The effect of lowering androgens, in particular DHT, on circulating IGF-I levels is unknown. We hypothesize that circulating IGF-1 in males is regulated by androgen which stimulate both hepatic and prostatic IGF-1 production and that DHT is the primary androgen responsible for this process. To test the relationship between testosterone and DHT in regulating circulating IGF-I levels, normal males will be compared to subjects in the following categories: I: 46 XY subjects with unique inherited conditions affecting androgen action. A) Homozygous and heterozygous males with a decrease in DHT secondary to an inherited gene defect in 5 alpha-reductase-2. B) 46 XY subjects with complete androgen insensitivity syndrome due to androgen receptor mutations blocking the actions of both testosterone and DHT at target areas. II: Males with BPH at baseline and after treatment with placebo or the 5 alpha-reductase inhibitor finasteride to lower DHT. III: Males who have had a prostatectomy for early organ confined prostate cancer. We also plan to examine the androgen control of the IGF-I pathway in prostate cancer and hypothesize that DHT is the androgen mainly responsible for regulation. Studies include: A) Males with metastatic prostate cancer before and after anti-androgen treatment. B) Prostatic cancer cells treated with either control vehicle, testosterone, DHT, testosterone plus 5alpha-reductase inhibitors, and DHT plus 50:-reductase inhibitors.

Back to top


Publications

Error Notice

If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.

Please contact us if this error persists.

We apologize for the inconvenience.
- The DCCPS Team.


Back to Top